[Mannan-binding lectin and MBL-associated serine protease-2].
In Denmark approximately 3,600 patients are diagnosed with colorectal cancer (CRC) every year. 75-80% of patients may undergo intended curative resection, but the disease recurs in about 40% within five years and the prognosis is poor. Hence, there is a need for biological markers that could be used for detection, evaluation of prognosis, therapy selection and monitoring. The serum proteins of the innate immune system mannan-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) are novel biomarkers under validation in CRC. Low preoperative MBL levels are predictive of pneumonia which subsequently is associated with poor survival. High MASP-2 levels predict recurrence and poor survival.
Jørgensen
Julie
J
Hvidovre Hospital, Gastroenheden, Kirurgisk Sektion 435, Hvidovre. frk@doktor.dk
Ytting
Henriette
H
Steffensen
Rudi M
RM
Nielsen
Hans Jørgen
HJ
D014408:Biomarkers, Tumor / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood* / Q000276:immunology / Q000401:mortality / Q000601:surgery; D006801:Humans; D037601:Mannose-Binding Lectin / Q000097:blood*; D050606:Mannose-Binding Protein-Associated Serine Proteases / Q000032:analysis*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000276:immunology; D011014:Pneumonia / Q000209:etiology; D011183:Postoperative Complications / Q000209:etiology; D011379:Prognosis
D014408:Biomarkers, Tumor; D037601:Mannose-Binding Lectin; C105296:MASP2 protein, human; D050606:Mannose-Binding Protein-Associated Serine Proteases